Related Experiment Video
Updated: Apr 30, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
Elevated Lipoprotein(a) and Cardiovascular Outcomes After Percutaneous Coronary Intervention: A Systematic Review
Mohamed A Alshibane1, Mohamed Abdelrahman Mohamed Ali2, Mohamed Ahmed3
1Biomedical Sciences, University of Reading, Reading, GBR.
Insights
Elevated Lipoprotein(a) (Lp(a)) significantly increases cardiovascular risks after percutaneous coronary intervention (PCI). Aggressive low-density lipoprotein cholesterol (LDL-C) lowering may reduce this risk, suggesting routine Lp(a) measurement for better risk stratification in PCI patients.
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
- Lipidology
Background:
- Lipoprotein(a) (Lp(a)) is a genetically determined lipoprotein linked to atherosclerosis and thrombosis.
- The prognostic significance of elevated Lp(a) in patients undergoing percutaneous coronary intervention (PCI) requires further elucidation.
Purpose of the Study:
- To systematically review and evaluate the association between elevated Lp(a) levels and cardiovascular outcomes following PCI.
Main Methods:
- A comprehensive literature search was performed across major databases (PubMed, Embase, Scopus, IEEE Xplore, Web of Science) for studies published between 2021 and 2025.
- Included were observational studies assessing Lp(a) and cardiovascular outcomes in PCI patients, with quality assessed by the Newcastle-Ottawa Scale (NOS).
- Eight studies involving 23,421 patients were analyzed, with Lp(a) thresholds varying from ≥30 mg/dL to ≥50 mg/dL.
Main Results:
- Seven of eight studies found a significant positive association between elevated Lp(a) and adverse cardiovascular events (MACEs), with hazard ratios ranging from 1.14 to 4.29.
- Elevated Lp(a) correlated with increased risks of myocardial infarction, stent thrombosis, and repeat revascularization.
- The prognostic impact of Lp(a) was most significant in high-risk patients and those with diabetes; aggressive low-density lipoprotein cholesterol (LDL-C) lowering may attenuate this risk.
Conclusions:
- Elevated Lp(a) is an independent predictor of adverse cardiovascular outcomes post-PCI.
- Routine Lp(a) measurement could aid in risk stratification and secondary prevention strategies for PCI patients.
- Further prospective and interventional studies are necessary to confirm these findings and guide clinical practice.
Abstract:
Lipoprotein(a) (Lp(a)) is a genetically determined lipoprotein with proatherogenic and prothrombotic properties. Its prognostic role in patients undergoing percutaneous coronary intervention (PCI) remains incompletely defined. This systematic review evaluates the association between elevated Lp(a) and cardiovascular outcomes after PCI. A comprehensive search of PubMed, Embase, Scopus, IEEE Xplore, and Web of Science was conducted for studies published between 2021 and 2025. Observational studies evaluating elevated Lp(a) and cardiovascular outcomes in PCI patients were included. Methodological quality was assessed using the Newcastle-Ottawa Scale (NOS). Eight studies comprising 23,421 patients were included. Elevated Lp(a) thresholds ranged from ≥30 mg/dL to ≥50 mg/dL. Seven studies demonstrated a significant positive association between elevated Lp(a) and adverse outcomes, with hazard ratios for major adverse cardiovascular events (MACEs) ranging from 1.14 to 4.29. Elevated Lp(a) was consistently associated with increased risks of myocardial infarction (HR 1.79), stent thrombosis (HR 1.83), and repeat revascularisation. One study in patients with well-controlled low-density lipoprotein cholesterol (LDL-C; <70 mg/dL) found no significant association. Subgroup analyses revealed that the prognostic value of Lp(a) was most pronounced in high-risk patients and those with diabetes. One study demonstrated that a greater decrease in Lp(a) over 12 months was associated with lower MACE risk. NOS assessment rated seven studies as high quality and one as moderate quality. Elevated Lp(a) is independently associated with increased risk of adverse cardiovascular outcomes after PCI, although this risk may be attenuated by aggressive LDL-C lowering. These findings may support the consideration of routine Lp(a) measurement in PCI patients for risk stratification and to help inform secondary prevention strategies, although confirmation from prospective and interventional studies is warranted.
Related Concept Videos
Coronary Artery Disease I: Introduction
Coronary Artery Disease IV: Preventive Measures
Coronary Artery Disease V: Interprofessional Care
Atherosclerosis I: Introduction
Atherosclerosis III: Management
Peripheral Artery Disease III: Interprofessional Care

